世界の分子診断市場（～2018）...市場調査レポートについてご紹介

Table Of Contents

1 Introduction (Page No. – 17)
1.1 Objectives of the Study
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Market Scope
1.6 Research Methodology
1.6.1 Market Size Estimation & Data Triangulation
1.6.2 Key Data From Secondary Sources
1.6.3 Key Data Points From Primary Sources
1.6.4 Assumptions

2 Executive Summary (Page No. – 28)

3 Premium Insight (Page No. – 32)

4 Market Overview (Page No. – 41)
4.1 Introduction
4.2 Market Segmentation
4.3 Market Dynamics
4.3.1 Drivers
4.3.1.1 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.3.1.2 Development of Biomarker Identification and Advancements in Molecular Techniques
4.3.1.3 Proteomics and Genomics Technology Research to Goad the Molecular Testing Market
4.3.1.4 Increase in AGing Population to Spur Growth of the Molecular Diagnostics Market
4.3.1.5 Reformations in the Reimbursement System
4.3.2 Restraints
4.3.2.1 Increased Costs of Molecular Diagnostics tools With New and Complex Platforms Demand Skilled Labor and Mandatory Training
4.3.2.2 Reimbursement Issues
4.3.2.3 Complex Regulatory Framework to Delay Approvals of New Molecular Diagnostic Tests
4.3.3 Opportunities
4.3.3.1 Extending the Reach of Molecular Diagnostics
4.3.3.2 Emerging Technologies Can Soon Gain Importance in Molecular Diagnostic Tests
4.3.4 Threats
4.3.4.1 Lack of Budget and Labor
4.3.4.2 Stringent Regulatory Framework to Stifle the Growth of Mdx Market
4.4 Market Share Analysis
4.5 Molecular Diagnostic Laboratories and Tests
4.6 End-User Analysis
4.7 Effects of Obamacare on the Molecular Diagnostics Market

5 Global Molecular Diagnostics Market, By Application (Page No. – 57)
5.1 Introduction
5.2 Infectious Diseases
5.2.1 Hepatitis B Virus (HBV)
5.2.2 Hepatitis C Virus (HCV)
5.2.3 Human Immunodeficiency Virus (HIV)
5.2.4 Tuberculosis (TB)
5.2.5 Chlamydia Trachomatis and Neisseria Gonorrhea (CT/NG)
5.2.6 Human Papillomavirus (HPV)
5.2.7 Methicillin-Resistant Staphylococcus Aureus (MRSA)
5.2.8 Others
5.3 oncology
5.3.1 Prostate Cancer
5.3.2 Breast Cancer
5.3.3 Colorectal Cancer
5.3.4 Others
5.4 Genetics
5.5 Blood Screening
5.6 Microbiology
5.7 Others

6 Global Molecular Diagnostics Market, By Technology (Page No. – 76)
6.1 Introduction
6.2 Polymerase Chain Reaction (PCR)
6.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
6.4 Microarrays
6.5 Hybridization (in Situ Hybridization and Fluorescence in Situ Hybridization)
6.6 Dna Sequencing & Next-Generation Sequencing
6.7 Others

7 Global Molecular Diagnostics Market, By Product Type (Page No. – 89)
7.1 Introduction
7.2 Instruments
7.3 Reagents
7.4 Services & Software

8 Geographic Analysis (Page No. – 97)
8.1 Introduction
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 U.K.
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia
8.4.1 Japan
8.4.2 India
8.4.3 China
8.4.4 Rest of Asia (ROA)
8.5 Rest of the World (ROW)
8.5.1 Latin America
8.5.2 Pacific
8.5.3 Middle East & Africa

9 Competitive Landscape (Page No. – 164)
9.1 Introduction
9.2 New Product Launch
9.3 Mergers & Acquisitions
9.4 Agreement/Partnership/Collaboration
9.5 Expansion
9.6 Other Developments

10 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)* (Page No. – 203)
10.1 Abbott Diagnostics, Inc.
10.2 Beckman Coulter, Inc.
10.3 Becton, Dickinson & Co.
10.4 Biomérieux Business Overview
10.5 Cepheid, Inc.
10.6 Gen-Probe, Inc. (Hologic, Inc.)
10.7 Novartis AG
10.8 Qiagen
10.9 Roche Diagnostics
10.1 Siemens Healthcare

*Details on Financials, Product & Services, Strategy, & Developments Might Not Be Captured in Case of Unlisted Companies.